
Sign up to save your podcasts
Or
Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.
5
66 ratings
Christopher Bunick, MD, PhD, LiVDerm faculty and member of the SBS Planning Committee, shares key takeaways from his session at the SBS 2022 event regarding IL-13 inhibitors for treatment of AD and the underlying disease pathogenesis.
6,885 Listeners
365,253 Listeners
9,359 Listeners
135 Listeners
28,354 Listeners